Introduction: Oral squamous cell carcinoma is one of the most widespread cancer which totalizes more than 90% of oral malignancies. Therefore, the conception of detaining or preventing the malignant transformation remains a viable target for future. Oxaliplatin is a third-generation platinum based chemotherapy cure that has value in the treatment against several forms of neoplasms. It forms intrastrand links between two adjoining DNA bases, hence disrupting its replication and transcription.
Aim of the study: The current work was carried out to report the oxaliplatin drug as a chemotherapeutic agent during DMBA-induced carcinoma in hamster buccal pouch, utilizing histopathology and flow cytometry analysis.
Material and methods: A total of 60 Syrian hamsters distributed as 2 animals examined for the normal pouch mucosa and 58 hamsters divided into; 6 experiments for Group I, their pouches were painted only with mineral oil. The remaining 52 animals for Group II, treated by DMBA mixed in a mineral oil. After 6 weeks, the hamsters separated into 2 subgroups; Group IIA, were persisted operated in DMBA. Group IIB, were employed to DMBA and injected with oxaliplatin.
Results: Oxaliplatin revealed effectiveness and tolerance in turn down the DMBA carcinogenesis procedure. Additionally, the chemotherapeutic results of oxaliplatin detected a significant reduction relation to the DNA aneuploidy and the S-phase fraction throughout the tumorigenic activity.
Conclusion: Oxaliplatin provided a proper strategy as a chemotherapeutic curing for control oral carcinogenesis process with a notable reduction of cancer incidence through reducing the nuclear proliferation activity and induction of cellular apoptosis.